Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

141.49USD
1:30am IST
Change (% chg)

$1.83 (+1.31%)
Prev Close
$139.66
Open
$139.16
Day's High
$142.00
Day's Low
$138.52
Volume
286,511
Avg. Vol
685,550
52-wk High
$197.00
52-wk Low
$125.84

Latest Key Developments (Source: Significant Developments)

Allergan Acquires Envy Medical Inc
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Allergan plc ::ALLERGAN ACQUIRES ENVY MEDICAL, INC., ADDING SKIN RESURFACING DERMALINFUSION SYSTEM TO BEST-IN-CLASS MEDICAL AESTHETICS PORTFOLIO.  Full Article

Allergan Says Believe Appaloosa Attempting To "Undermine Our CEO" And Pushing For A "Firesale" Of Co
Tuesday, 26 Mar 2019 

March 25 (Reuters) - Allergan plc ::ALLERGAN PLC - BELIEVE APPALOOSA ATTEMPTING TO "UNDERMINE OUR CEO" AND PUSHING FOR A "FIRESALE" OF CO.  Full Article

Allergan Adopts Policy For Chairman To Be Independent Member Of Board
Saturday, 23 Mar 2019 

March 22 (Reuters) - Allergan plc ::ALLERGAN - ADOPTED POLICY TO PROVIDE THAT CHAIRMAN OF BOARD SHALL BE AN INDEPENDENT MEMBER OF BOARD TO BE PHASED IN WITH NEXT LEADERSHIP TRANSITION..ALLERGAN - BOARD FORMED MERGERS AND ACQUISITIONS COMMITTEE TO PROVIDE FOCUSED OVERSIGHT ON MERGERS, ACQUISITIONS, DIVESTITURES, OTHER TRANSACTIONS.ALLERGAN - BOARD ADOPTED ENHANCEMENTS TO LEAD INDEPENDENT DIRECTOR ROLE, RESPONDING TO SHAREHOLDER INPUT AND FURTHER STRENGTHENING THE POSITION..ALLERGAN - CATHERINE KLEMA WILL NOT BE STANDING FOR RE-ELECTION TO BOARD AT 2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS..ALLERGAN - THOMAS FREYMAN WILL BECOME CHAIR OF COMPENSATION COMMITTEE OF THE BOARD, EFFECTIVE AS OF KLEMA’S RETIREMENT FROM BOARD.  Full Article

Allergan Announces FDA Approval Of Avycaz For Pediatric Patients
Monday, 18 Mar 2019 

March 18 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES FDA APPROVAL OF AVYCAZ® (CEFTAZIDIME AND AVIBACTAM) FOR PEDIATRIC PATIENTS.ALLERGAN ANNOUNCES FDA APPROVAL OF AVYCAZ® (CEFTAZIDIME AND AVIBACTAM) FOR PEDIATRIC PATIENTS.ALLERGAN PLC - LABEL NOW INCLUDES NEW DATA ON USE OF AVYCAZ FOR TREATMENT OF CUTI AND CIAI IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER.ALLERGAN PLC - FROM FINDINGS, NO NEW SAFETY CONCERNS WERE IDENTIFIED IN PEDIATRIC PATIENTS..  Full Article

Appaloosa LP Sends Letter To Allergan About Resolution To Separate Roles Of Chairman, CEO
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Appaloosa LP::APPALOOSA LP SENDS LETTER TO ALLERGAN BOARD IN RESPONSE TO RESOLUTION TO SEPARATE ROLES OF CHAIRMAN AND CEO.APPALOOSA LP, IN LETTER TO ALLERGAN, SAYS SEEKS A MORE IMMEDIATE SEPARATION OF CHAIR AND CEO.SAYS WILL NOT WITHDRAW ITS ALLERGAN PROPOSALS FROM THIS YEAR’S PROXY STATEMENT.IF ALLERGAN BOARD "UNABLE OR UNWILLING" TO FIND SUITABLE REPLACEMENT, IT IS "FIDUCIARY OBLIGATION" TO EXPLORE OTHER OPTIONS, INCLUDING MERGER/SALE.BOB HUGIN WOULD HAVE BEEN A "CREDIBLE CANDIDATE" FOR ALLERGAN CHAIRMAN GIVEN "HIS STANDING IN THE INDUSTRY".  Full Article

Allergan PLC - Robert J. Hugin Appointed To Allergan Board Of Directors
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Allergan plc ::ROBERT J. HUGIN APPOINTED TO ALLERGAN BOARD OF DIRECTORS.ALLERGAN PLC - COMPANY TO RECOMMEND FOR A SHAREHOLDER PROPOSAL TO PHASE IN INDEPENDENT BOARD CHAIR AT NEXT LEADERSHIP TRANSITION.ALLERGAN PLC - HUGIN WAS FORMERLY CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF CELGENE CORPORATION.  Full Article

Hungary's Richter signs deal to sell Levosert in Latin America
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt ::Has signed a distribution and supply agreement with a wholly-owned subsidiary of Allergan <<>> to sell its Levosert medicine in Latin America..Sales-related royalties and milestone payments will become payable to Allergan following the launch of the product..  Full Article

Allergan Says Board Of Directors Has Received Appaloosa's Proposal And Is "Committed To Continuing To Engage With Them"
Saturday, 9 Feb 2019 

Feb 8 (Reuters) - Allergan plc ::ALLERGAN PLC - IN RESPONSE TO INQUIRIES REGARDING APPALOOSA'S PRESS RELEASE, ALLERGAN MADE STATEMENT.ALLERGAN PLC - BOARD OF DIRECTORS HAS RECEIVED APPALOOSA'S PROPOSAL AND IS "COMMITTED TO CONTINUING TO ENGAGE WITH THEM".ALLERGAN PLC - BOARD OF DIRECTORS IS COMMITTED TO STRONG GOVERNANCE PRACTICES AND INDEPENDENT BOARD LEADERSHIP.  Full Article

Health Canada Safety Review Finds Possible Link Between Fibristal And Risk Of Liver Injury
Friday, 11 Jan 2019 

Jan 11 (Reuters) - Health Canada::HEALTH CANADA - INFORMING CANADIANS THAT ITS SAFETY REVIEW OF FIBRISTAL FOUND POSSIBLE LINK BETWEEN ITS USE & RISK OF A RARE BUT SERIOUS LIVER INJURY.HEALTH CANADA - INITIATED ITS SAFETY REVIEW OF FIBRISTAL AFTER RECEIVING 4 INTERNATIONAL REPORTS OF LIVER INJURY LEADING TO LIVER TRANSPLANTS.HEALTH CANADA - HAS WORKED WITH THE MANUFACTURER TO UPDATE CANADIAN PRODUCT SAFETY INFORMATION FOR FIBRISTAL, WHICH INCLUDE NEW RESTRICTIONS FOR USE.  Full Article

Richter sees U.S. talks on Esmya drug around end-year -website
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt Chairman Erik Bogsch says in interview on website Portfolio.hu::CONSULTATION BETWEEN ITS PARTNER ALLERGAN AND U.S. HEALTH REGULATOR ON ESMYA DRUG LIKELY TO TAKE PLACE AT THE END OF 2018 OR EARLY 2019 .RICHTER IS LOOKING FOR PRODUCT ACQUISITION OPPORTUNITIES AS IT HAS THE NECESSARY FINANCIAL RESOURCES FOR THAT.RICHTER ALMOST SOLELY FOCUSES ON GYNAECOLOGY IN SEEKING PRODUCT ACQUISITIONS.  Full Article

Photo

Proxy firms back Allergan in fight against Appaloosa

Two leading shareholder advisory firms threw their support behind Allergan Plc's management by recommending that investors vote against billionaire investor David Tepper's proposal that the Botox maker immediately split the roles of chief executive officer and chairman.